군발두통 신규 치료법 보고서(2026년)(2분기판)

The global cluster headache emerging therapies market is expected to grow from USD 0.89 billion in 2026 at a 8.9% CAGR to a market value of USD 1.91 billion in 2035.

The emerging treatment landscape is evolving rapidly as pharmaceutical and biotechnology companies focus on therapies that reduce attack frequency, improve long-term disease control, and address the substantial unmet medical needs of patients with episodic and chronic cluster headache.

Cluster headache is a rare but highly debilitating primary headache disorder characterized by recurrent episodes of severe unilateral pain accompanied by autonomic symptoms. Although acute treatments such as oxygen therapy and triptans remain standard of care, current preventive options are limited by tolerability, incomplete response, and safety concerns. Emerging therapies analysis provides comprehensive insights into investigational drugs, mechanisms of action, clinical development progress, pipeline maturity, sponsor activities, regulatory developments, and commercialization opportunities.

Market Drivers

Increasing Investment in Rare Neurological Disorders

Growing recognition of cluster headache as a rare neurological disease with high unmet clinical need is encouraging pharmaceutical companies to expand research and development activities. Orphan drug incentives and supportive regulatory pathways continue to stimulate pipeline growth.

Expansion of CGRP-Targeted Therapies

Calcitonin gene-related peptide (CGRP) has emerged as one of the most important therapeutic targets in cluster headache. Ongoing development of CGRP monoclonal antibodies and other targeted therapies is improving the potential for effective preventive treatment.

Growing Interest in Neuromodulation

Advances in non-invasive vagus nerve stimulation, occipital nerve stimulation, and sphenopalatine ganglion stimulation are expanding treatment options for patients who do not adequately respond to conventional pharmacological therapies.

Improved Understanding of Disease Biology

Progress in neuroscience research has enhanced understanding of hypothalamic dysfunction, trigeminovascular activation, and neuropeptide signaling, supporting development of more targeted therapeutic approaches.

Market Restraints

Limited Patient Population

Cluster headache is a rare disorder affecting approximately 0.1% of the global population, making patient recruitment for clinical trials challenging and increasing development costs.

Complex Clinical Trial Design

The episodic nature of the disease, fluctuating attack frequency, and relatively small patient population complicate clinical trial design and endpoint selection.

Regulatory Challenges

Emerging therapies require robust clinical evidence demonstrating long-term efficacy, safety, and meaningful improvements in attack prevention before obtaining regulatory approval.

Emerging Therapy and Technology Insights

The global cluster headache emerging therapies market can be segmented by development phase, mechanism of action, drug type, therapy type, and geography.

By development phase, the market includes preclinical, Phase I, Phase II, Phase III, and regulatory review-stage therapies. Clinical activity is increasingly concentrated in Phase II and Phase III programs as sponsors seek differentiated therapies capable of providing durable preventive benefits.

By mechanism of action, emerging therapies include CGRP-targeted therapies, serotonin receptor modulators, calcium channel modulators, neuromodulation therapies, and other novel mechanisms. CGRP-directed therapies continue to dominate pipeline innovation because they directly target neurovascular pathways involved in cluster headache pathophysiology.

By drug type, the pipeline consists of small molecules, monoclonal antibodies, biologics, peptide therapies, and device-based therapies. Biologics and neuromodulation technologies represent rapidly expanding areas of innovation.

By therapy type, investigational products focus on acute treatment, preventive treatment, bridge therapy, and combination approaches. Preventive therapies account for the greatest development activity because reducing attack frequency remains a major unmet clinical need.

Technological advances including artificial intelligence-assisted drug discovery, digital headache diaries, wearable monitoring technologies, decentralized clinical trials, and biomarker research are improving patient selection, clinical trial efficiency, and therapeutic development.

Emerging Therapy Trends

The cluster headache pipeline continues to evolve toward targeted and personalized neurological therapies.

Key development trends include:

• Expansion of CGRP monoclonal antibody development.
• Growing adoption of non-invasive neuromodulation technologies.
• Increasing investment in orphan neurological disease research.
• Greater use of artificial intelligence in target identification.
• Expansion of biomarker-driven clinical development.
• Increasing focus on chronic cluster headache.
• Greater integration of patient-reported outcome measures in clinical trials.

Strategic collaborations among pharmaceutical companies, biotechnology firms, medical device developers, and academic research organizations continue to accelerate innovation and strengthen the global development pipeline.

Regional Insights

North America remains the leading region for cluster headache emerging therapies because of advanced neurology infrastructure, strong clinical research capabilities, favorable orphan drug policies, and high pharmaceutical investment.

Europe continues to maintain a strong position through established headache research centers, collaborative neuroscience programs, and increasing adoption of preventive biological therapies.

Asia-Pacific is expected to register the fastest growth during the forecast period owing to expanding healthcare investment, improving neurological care, increasing awareness of rare neurological disorders, and growing participation in multinational clinical trials.

Latin America and the Middle East & Africa are gradually improving access to diagnosis and specialist neurological care, creating future opportunities for emerging therapies.

Competitive Landscape

The cluster headache emerging therapies landscape includes multinational pharmaceutical companies, biotechnology companies, medical device manufacturers, academic institutions, and specialty neurology developers.

Organizations continue investing in CGRP-targeted therapies, neuromodulation devices, precision medicine, artificial intelligence-enabled drug discovery, and novel neuropeptide targets. Strategic licensing agreements, research collaborations, mergers and acquisitions, and commercialization partnerships remain central to accelerating therapeutic innovation and expanding global market presence.

Future Outlook

The future of the cluster headache emerging therapies market is expected to be shaped by advances in neurobiology, precision medicine, neuromodulation technologies, and targeted biologics. Continued research into CGRP signaling, hypothalamic mechanisms, inflammatory pathways, and wearable digital technologies is expected to improve disease management while supporting development of more effective preventive therapies.

Greater integration of real-world evidence, digital monitoring platforms, and patient-centered clinical endpoints is expected to accelerate regulatory approvals and commercialization opportunities throughout the forecast period.

Conclusion

The global Cluster Headache Emerging Therapies Analysis market is expected to experience substantial growth through 2035, supported by increasing investment in rare neurological diseases, advances in CGRP-targeted therapies, expanding neuromodulation technologies, and growing understanding of disease biology. Although challenges related to small patient populations, complex clinical trial design, and regulatory requirements remain, continued innovation in targeted therapeutics, biologics, and precision medicine is expected to transform the future treatment landscape for patients with cluster headache.

Key Benefits of this Report

• Comprehensive analysis of the global cluster headache emerging therapies landscape.
• Detailed evaluation of investigational therapies, mechanisms of action, and pipeline maturity.
• Competitive assessment of sponsor activities, strategic collaborations, and clinical development progress.
• Insights into regulatory developments, commercialization opportunities, and future innovation trends.
• Valuable resource for pharmaceutical companies, biotechnology firms, medical device manufacturers, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Pipeline benchmarking, competitive intelligence, licensing and partnership evaluation, portfolio optimization, clinical development planning, commercialization strategy, regulatory planning, investment analysis, and identification of future market opportunities.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the cluster headache emerging therapies landscape by development phase, mechanism of action, drug type, therapy type, and geography
• Evaluation of investigational therapies, clinical development progress, pipeline maturity, innovation trends, and sponsor activities
• Assessment of strategic collaborations, licensing agreements, regulatory developments, commercialization strategies, and competitive positioning
• Analysis of CGRP-targeted therapies, neuromodulation technologies, biologics, precision medicine approaches, and future commercialization opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Disease Burden Overview
• 1.4 Approved Treatment Landscape Overview
• 1.5 Emerging Therapies Overview
• 1.6 Key Growth Opportunities
• 1.7 Strategic Recommendations

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Cluster Headache
  • 2.1.1 Definition and Clinical Characteristics
  • 2.1.2 Historical Perspective
  • 2.1.3 Disease Classification
    • 2.1.3.1 Episodic Cluster Headache
    • 2.1.3.2 Chronic Cluster Headache
• 2.2 Disease Pathophysiology
  • 2.2.1 Role of the Trigeminal Autonomic Reflex
  • 2.2.2 Hypothalamic Dysfunction
  • 2.2.3 Neurovascular Mechanisms
  • 2.2.4 Calcitonin Gene-Related Peptide (CGRP) Pathway
• 2.3 Etiology and Risk Factors
• 2.4 Signs and Symptoms
• 2.5 Diagnosis and Diagnostic Criteria
  • 2.5.1 International Classification of Headache Disorders (ICHD) Criteria
  • 2.5.2 Differential Diagnosis
  • 2.5.3 Diagnostic Challenges
• 2.6 Epidemiology of Cluster Headache
  • 2.6.1 Prevalence Analysis
  • 2.6.2 Incidence Analysis
  • 2.6.3 Gender-Based Epidemiology
  • 2.6.4 Age-Based Epidemiology
  • 2.6.5 Epidemiology by Disease Subtype
    • 2.6.5.1 Episodic Cluster Headache
    • 2.6.5.2 Chronic Cluster Headache
  • 2.6.6 Disease Burden and Quality of Life Impact

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
  • 3.2.1 Rising Disease Awareness and Diagnosis Rates
  • 3.2.2 Expanding Use of Targeted Therapies
  • 3.2.3 Growing Clinical Research Activities
• 3.3 Market Restraints
  • 3.3.1 Limited Availability of Approved Therapies
  • 3.3.2 High Treatment Costs
  • 3.3.3 Challenges in Clinical Trial Recruitment
• 3.4 Market Opportunities
  • 3.4.1 Development of Novel Mechanism-Based Therapies
  • 3.4.2 Expansion in Emerging Markets
  • 3.4.3 Advances in Neuromodulation Technologies
• 3.5 Market Challenges
• 3.6 Porter's Five Forces Analysis
• 3.7 PESTLE Analysis
• 3.8 Value Chain Analysis

4. Commercial & Market Access

• 4.1 Commercial Landscape Overview
• 4.2 Pricing Analysis
• 4.3 Reimbursement Scenario
• 4.4 Market Access Challenges
• 4.5 Health Technology Assessment Trends
• 4.6 Patient Assistance and Access Programs
• 4.7 Distribution and Commercialization Models

5. Innovation & Pipeline Landscape

• 5.1 Overview of Emerging Therapies
• 5.2 Pipeline Analysis by Development Phase
  • 5.2.1 Phase I Therapies
  • 5.2.2 Phase II Therapies
  • 5.2.3 Phase III Therapies
• 5.3 Pipeline Analysis by Modality
  • 5.3.1 Monoclonal Antibodies
  • 5.3.2 Small Molecules
  • 5.3.3 Neuromodulation Devices
  • 5.3.4 Intranasal Therapies
• 5.4 Pipeline Analysis by Mechanism of Action
  • 5.4.1 CGRP Pathway Inhibitors
  • 5.4.2 Serotonin Receptor Agonists
  • 5.4.3 Neuromodulation-Based Approaches
  • 5.4.4 Other Novel Mechanisms
• 5.5 Clinical Trial Landscape
  • 5.5.1 Ongoing Clinical Trials
  • 5.5.2 Completed Clinical Trials
  • 5.5.3 Trial Design Trends
• 5.6 Patent Landscape Analysis
• 5.7 Innovation Trends and Future Technologies

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Acute Treatment Options
  • 6.2.1 Oxygen Therapy
  • 6.2.2 Triptans
  • 6.2.3 Intranasal Therapies
• 6.3 Preventive Treatment Options
  • 6.3.1 Calcium Channel Blockers
  • 6.3.2 CGRP Monoclonal Antibodies
  • 6.3.3 Corticosteroids
  • 6.3.4 Other Preventive Therapies
• 6.4 Neuromodulation Therapies
• 6.5 Treatment Algorithm
• 6.6 Unmet Clinical Needs

7. Global Cluster Headache Emerging Therapies Report Size & Forecast

• 7.1 Global Market Size Analysis (2021-2035)
• 7.2 Global Market Forecast (2026-2035)
• 7.3 Market Attractiveness Analysis
• 7.4 Market Forecast by Therapy Type
• 7.5 Market Forecast by Route of Administration
• 7.6 Market Forecast by End User
• 7.7 Market Forecast by Distribution Channel

8. Global Cluster Headache Emerging Therapies Report Segmentation

• 8.1 By Treatment Type
  • 8.1.1 Acute Treatment
  • 8.1.2 Preventive Treatment
  • 8.1.3 Bridge Treatment
• 8.2 By Drug Class
  • 8.2.1 Triptans
  • 8.2.2 CGRP Monoclonal Antibodies
  • 8.2.3 Calcium Channel Blockers
  • 8.2.4 Corticosteroids
  • 8.2.5 Other Drug Classes
• 8.3 By Route of Administration
  • 8.3.1 Oral
  • 8.3.2 Injectable
  • 8.3.3 Intranasal
• 8.4 By End User
  • 8.4.1 Hospitals
  • 8.4.2 Speciality Clinics
  • 8.4.3 Homecare Settings
  • 8.4.4 Others
• 8.5 By Distribution Channel
  • 8.5.1 Hospital Pharmacies
  • 8.5.2 Retail Pharmacies
  • 8.5.3 Online Pharmacies

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size & Growth
  • 9.1.2 Demand Drivers
  • 9.1.3 Regional Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size & Growth
  • 9.2.2 Demand Drivers
  • 9.2.3 Regional Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size & Growth
  • 9.3.2 Demand Drivers
  • 9.3.3 Regional Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size & Growth
  • 9.4.2 Demand Drivers
  • 9.4.3 Regional Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size & Growth
  • 9.5.2 Demand Drivers
  • 9.5.3 Regional Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Regulatory Overview
• 11.2 United States Regulatory Framework
  • 11.2.1 FDA Drug Approval Pathways
  • 11.2.2 Orphan Drug and Fast Track Designations
• 11.3 Europe Regulatory Framework
  • 11.3.1 EMA Approval Process
  • 11.3.2 Orphan Medicinal Product Regulations
• 11.4 Japan Regulatory Framework
  • 11.4.1 PMDA Approval Pathways
• 11.5 India Regulatory Framework
  • 11.5.1 CDSCO Approval Process
• 11.6 China Regulatory Framework
  • 11.6.1 NMPA Approval Process
• 11.7 Reimbursement and Pricing Policies
• 11.8 Clinical Trial Regulations

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Strategic Initiatives
  • 12.3.1 Collaborations and Partnerships
  • 12.3.2 Licensing Agreements
  • 12.3.3 Mergers and Acquisitions
• 12.4 Pipeline Competitiveness Matrix
• 12.5 SWOT Analysis

13. Company Profiles

• 13.1 GlaxoSmithKline plc
  • 13.1.1 Company Overview
  • 13.1.2 Approved Drugs and Key Indications
  • 13.1.3 Cluster Headache-Related Research Activities
  • 13.1.4 Pipeline Assets (Verified)
  • 13.1.5 Recent Developments
• 13.2 Medtronic
  • 13.2.1 Company Overview
  • 13.2.2 Approved Devices and Key Indications
  • 13.2.3 Neuromodulation Portfolio
  • 13.2.4 Pipeline and Innovation Activities
  • 13.2.5 Recent Developments
• 13.3 Eli Lilly and Company
  • 13.3.1 Company Overview
  • 13.3.2 Approved Drugs and Key Indications
  • 13.3.3 Cluster Headache Portfolio
  • 13.3.4 Pipeline Assets (Verified)
  • 13.3.5 Recent Developments
• 13.4 electroCore, Inc.
  • 13.4.1 Company Overview
  • 13.4.2 Approved Devices and Indications
  • 13.4.3 Cluster Headache Portfolio
  • 13.4.4 Pipeline and Innovation Activities
  • 13.4.5 Recent Developments
• 13.5 Pfizer Inc.
  • 13.5.1 Company Overview
  • 13.5.2 Approved Drugs and Key Indications
  • 13.5.3 Neurology Portfolio
  • 13.5.4 Pipeline Assets (Verified)
  • 13.5.5 Recent Developments
• 13.6 Grunenthal GmbH
  • 13.6.1 Company Overview
  • 13.6.2 Approved Drugs and Key Indications
  • 13.6.3 Headache and Pain Portfolio
  • 13.6.4 Pipeline Assets (Verified)
  • 13.6.5 Recent Developments
• 13.7 Viatris Inc.
  • 13.7.1 Company Overview
  • 13.7.2 Approved Products and Key Indications
  • 13.7.3 Neurology Portfolio
  • 13.7.4 Pipeline Assets (Verified)
  • 13.7.5 Recent Developments
• 13.8 Autonomic Technologies Inc.
  • 13.8.1 Company Overview
  • 13.8.2 Approved and Investigational Technologies
  • 13.8.3 Cluster Headache Programs
  • 13.8.4 Clinical Development Status
  • 13.8.5 Recent Developments
• 13.9 Zosano Pharma Corp.
  • 13.9.1 Company Overview
  • 13.9.2 Approved Products and Key Indications
  • 13.9.3 Headache-Related Research Programs
  • 13.9.4 Pipeline Assets (Verified)
  • 13.9.5 Recent Developments
• 13.10 Bausch Health Companies Inc.
  • 13.10.1 Company Overview
  • 13.10.2 Approved Drugs and Key Indications
  • 13.10.3 Neurology Portfolio
  • 13.10.4 Pipeline Assets (Verified)
  • 13.10.5 Recent Developments

14. Future Outlook

• 14.1 Future Market Projections
• 14.2 Emerging Technologies
• 14.3 Next-Generation Therapeutic Strategies
• 14.4 Opportunities in Precision Medicine
• 14.5 Investment Outlook
• 14.6 Analyst Recommendations

15. Methodology

• 15.1 Research Objectives
• 15.2 Research Design
• 15.3 Secondary Research Methodology
• 15.4 Primary Research Methodology
• 15.5 Data Validation and Triangulation
• 15.6 Forecasting Methodology
• 15.7 Assumptions and Limitations
• 15.8 Abbreviations and Definitions